TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...

Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected ...

Second, bleeding may have occurred, further reducing HCT and RBC levels. The observed bruising in this ... the long-term use of this drug requires that the benefits and risks be carefully weighed to ...

February 20: ADIA Nutrition launched Adia Labs LLC, unveiling Adia Vita-a branded stem cell product containing 100 million viable cells and 3 trillion exosomes per dose for clinical research and ...

Post-HCT maintenance therapies were allowed if planned to initiate after day 90 post-transplant, given conclusion of study drug administration around this time. Use of antithymocyte globulin or ...

In September, Akeso, a little-known Chinese biotech company founded nearly a decade ago shook up the biotech sector with its new lung cancer drug. Ivonescimab, the new drug, was found in a trial ...

and other agencies to confirm the regulatory status of an HCT/P and that it meets the criteria for regulation solely under Section 361 of the Public Health Services Act, versus requiring premarket ...

Celularity (CELU) received recommendation letters from the US Food and Drug Administration, or FDA, Tissue Reference Group, or TRG, in response to ...